Printer Friendly

MHLW APPROVES DIAMONDBACK 360 CORONARY OAS.

Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Diamondback 360 Coronary Orbital Atherectomy System (OAS) with Classic Crown (Classic Crown) and ViperWire Advance Coronary Guidewire FlexTip (FlexTip).

Classic Crown is the market-leading coronary atherectomy device in the United States. Classic Crown utilizes a 1.25mm eccentrically mounted diamond-coated crown and a patented combination of centrifugal force and differential sanding to safely modify arterial calcium. This device now features GlideAssist[R], which allows for tracking, easier removal and smoother repositioning of the device particularly in challenging anatomies.

FlexTip is a unique new atherectomy guidewire with a nitinol core and shapeable stainless-steel tip for increased flexibility and kink-resistance, improved navigation, and reduced guidewire bias in complex coronary vessels. Classic Crown can also be used with ViperWire Advance[R] Coronary Guidewire FlexTip.

Dr. Shigero Saito, of Shonan Kamakura General Hospital, Kamakura City, Japan and National Principal Investigator of CSI's COAST trial, who treated the first patient with both of the newly approved products, said, Using the new ViperWire Advance FlexTip combined with the GlideAssist feature on Classic Crown allowed me to easily track the OAS device through tortuous coronary vessels and effectively modify a calcified lesion facilitating stent deployment.

Scott Ward, Chairman, President and Chief Executive Officer of CSI, concluded, We are excited to introduce the Classic Crown and FlexTip in Japan the first market with an opportunity to use these two products together. Ten to 20 percent of the 280,000 Japanese patients who undergo percutaneous coronary interventions, or PCIs, each year have severely calcified coronary lesions. Multiple studies have shown that calcium is associated with poor PCI outcomes. Orbital atherectomy modifies calcific plaque to improve PCI results. Physicians in Japan may now consider our Classic Crown or Micro Crown to provide durable and cost-effective results for this large and underserved patient population.

CSI received MHLW approval for the Diamondback 360[R] Coronary OAS Micro Crown in March 2017 and reimbursement approval in February 2018. In November 2016, CSI announced that Medikit, Co., Ltd. signed an exclusive distribution agreement to sell its coronary and peripheral OAS in Japan.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's OAS treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the use of the Diamondback Orbital Atherectomy System in coronary arteries. The company received approval from Japan's Ministry of Health, Labor and Welfare (MHLW) approval the Diamondback 360[R] Coronary OAS Micro Crown in March 2017 and the Diamondback 360[R] Coronary OAS with Classic Crown and ViperWire Advance[R] Coronary Guidewire FlexTip in December 2018. The Stealth 360[R] Peripheral Orbital Atherectomy System (OAS) received CE Mark in October 2014. Over 400,000 of CSI's OAS devices have been sold to leading institutions worldwide.

About Medikit Co., Ltd.

Established in 1973 and based in Tokyo, Medikit Co., Ltd. is a global medical technology company and is publicly-traded on the JASDAQ exchange (JASDAQ: 7749). Medikit's mission is to deliver the highest standards of excellence in operating as a health care company whose products and services help to enhance healthy lives by minimizing unnecessary suffering and death from disease. Medikit is a market leader in interventional products including vascular access devices such as hemodialysis catheters, intravenous catheters, sheaths and guiding catheters. Medikit products are sold in Japan, the United States and over 30 other countries. The company has R&D and manufacturing capabilities in Japan and Vietnam with more than 1,300 consolidated employees. For more information, visit the company's website at www.medikit.co.jp.

For more information, visit www.csi360.com or call 877/274-0901.
COPYRIGHT 2019 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Equipment Update
Geographic Code:9JAPA
Date:Feb 1, 2019
Words:675
Previous Article:AMRA RECEIVES U.S. FDA CLEARANCE FOR AMRA PROFILER.
Next Article:IMEC AND TNO UNVEIL DISPOSABLE HEALTH PATCH.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters